MRI outperformed micro-ultrasound in sensitivity and negative predictive value for prostate cancer detection. Micro-ultrasound offers a short learning curve and real-time lesion identification, ...

IsoPSA, a blood-based test, aids in diagnosing high-grade prostate cancer by analyzing PSA protein structural variants. FDA approval was based on a large-scale, prospective study and other validation ...

In this debut episode of The UroOnc Minute, host Adam Weiner, MD, a urologic oncologist and surgeon-scientist at Cedars-Sinai Medical Center, introduces listeners to a new Urology Times podcast ...

The PR.21 study found no significant difference in rPFS between 177Lu-PSMA-617 and docetaxel in mCRPC patients. 177Lu-PSMA-617 showed a higher PSA response rate compared to docetaxel, with 36% vs 16% ...

The NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy in MIBC patients did not negatively impact HRQOL outcomes. Significant improvement in event-free survival was observed with ...

Zoliflodacin, a first-in-class oral antibiotic, targets uncomplicated gonorrhea and has received FDA NDA acceptance and priority review status. Clinical trials ...

The survey examines urologists' treatment patterns and preferences for non–muscle invasive bladder cancer, providing valuable insights into current practices. Michael S. Cookson, MD, and Jason M.

“We're now entering an era of new types of technologies to treat BPH in a minimally invasive fashion,” says Dean Elterman, MD. “We're now entering an era of new types of technologies to treat BPH in a ...

“I think it does give us confidence that clinical trials can predict how these drugs will work in the real world," says Stephen J. Freedland, MD. “The challenge is, from a statistical study design ...